Helpline: 021-111-455-455

Buy Now

Consult Now

Empowering Control Preserving Metabolic Health

Targets hyperglycaemia and appetite dysregulation through GLP-1 receptor activation, delivering proven HbA1c reduction and durable metabolic outcomes.

Available in pre-filled pens and vials

Once weekly convenient dosing

Helpline: 021 111 455 455

Available in pre-filled pens and vials

Once weekly convenient dosing

Helpline: 021 111 455 455

Available in pre-filled pens and vials

Once weekly convenient dosing

Helpline: 021 111 455 455

Available in pre-filled pens and vials

Once weekly convenient dosing

Helpline: 021 111 455 455

Available in pre-filled pens and vials

Once weekly convenient dosing

Helpline: 021 111 455 455

Available in pre-filled pens and vials

Once weekly convenient dosing

Helpline: 021 111 455 455

Available in pre-filled pens and vials

Once weekly convenient dosing

Helpline: 021 111 455 455

About Sem-P (Semaglutide)

Sem-P (Semaglutide) is GLP-1 receptor agonist used to

Helps control blood sugar in Type 2 Diabetes Mellitus (with diet & exercise)
Reduces risk of major cardiovascular events (heart attack, stroke, death) in high-risk patients
Supports chronic weight management in:
1. Obesity
2. Overweight with comorbidities (e.g., hypertension, diabetes, dyslipidemia)
3. Used in MASH (Metabolic Dysfunction-Associated Steatohepatitis)

Mechanism of Action

Sem-P activates GLP-1 receptors through multiple complementary pathways to achieve comprehensive glucose homeostasis and metabolic regulation.

Glucose-Dependent Insulin Secretion

Enhances pancreatic β-cell insulin response

Glucagon Suppression

Suppresses excessive glucagon release

Central Appetite Regulation

Suppresses excessive glucagon release

Check your patient’s BMI

Use this calculator to check your patient’s body mass index (BMI), which can help you know your weight category.

Your BMI

0

<16<40

Check your BMI

Enter your height and weight to see your Body Mass Index (BMI)

How to use

Sem-P is available in two strengths, in both pre-filled pen and vial forms.

Proven Results

Once-weekly injections can lower average blood sugar (HbA1c) by:^[1]

↓ 2.1% with the 2 mg dose

↓ 1.9% with the 1 mg dose

Up to 70% of people reach the recommended blood sugar target (<7%) after 40 weeks with 2mg dosing added to their existing diabetes medicines.

Persistent Weight Reduction with Semaglutide over 40 weeks:^[2]

Patients receiving Semaglutide 1mg achieved an average weight reduction of 6 Kg
Patients receiving Semaglutide 2mg achieved an even greater average weight reduction of 6.9 Kg over 40 weeks

In people with metabolic fatty liver disease:^[3]

62.9% had inflammation improvement without worsening of scarring
36.8% had decrease in liver scarring without the worsening of inflammation

These improvements help prevent progression to advanced liver disease.

In people with Type 2 diabetes and early kidney disease, once-weekly treatment reduced the risk of:^{[4] [5]}

Onset of kidney failure
Death from kidney or heart causes

The overall risk reduction was 24%.

In people with diabetes and heart disease, this treatment reduced major heart complications such as heart attack, stroke, or cardiovascular death by 26%.^[6]

People with obesity-related heart failure experienced:^[7]

Fewer symptoms like breathlessness and fatigue
Better physical function
Significant weight loss

These improvements were observed alongside weight loss.

In people with obesity-related knee arthritis:^[8]

Weight dropped by 13.2%
Changes in knee pain were reported
Physical function improved significantly

Everything you need to know

Sem-P is administered once weekly via subcutaneous injection in the abdomen, thigh, or upper arm. The vial and Pre-filled pen are designed for self-administration and include built-in safety features. Rotate injection sites each week to minimize irritation. You should demonstrate the proper technique during your first appointment with your patient.

Like all medications, GLP-1 treatments can cause side effects. The most common are mild nausea, vomiting, abdominal pain, and decreased appetite which typically improve after the first few weeks.

Treatment begins with Sem-P 0.25mg weekly for 4 weeks to minimize side effects. Dosage is gradually increased (0.5mg, 1mg, up to 2mg) based on your tolerance and weight loss response. You will adjust your patient’s dose every 4 weeks until reaching the optimal therapeutic level.

Sem-P is contraindicated in patients with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Not recommended during pregnancy, breastfeeding, or for patients with severe gastroparesis. Discuss the complete medical history with your patient to ensure Sem-P is safe for them.

Yes, Sem-P may be used for people with prediabetes and obesity to help with weight loss and improve blood sugar control. It works by helping their body use insulin better and reducing appetite. The decision is made based on your patient’s health, weight goals, and blood sugar levels.

Reference

1 - Frías JP, Auerbach P, Bajaj HS, Fukushima Y, Lingvay I, Macura S, et al. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. The Lancet Diabetes & Endocrinology [Internet]. 2021 Sep;9(9):563–74.

2 - Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis. New England Journal of Medicine. 2025 Apr 30;392(21).

3 - Perkovic V, et al. Effects of semaglutide on chronic kidney disease in patients with type 2diabetes. N Engl J Med. 2024 May 24; 390(21):2011-2023. doi:10 1056/NEJMoa2403347.

4 - Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine [Internet]. 2016 Nov 10;375(19):1834–44.

5 - Kosiborod MN et al. N Engl J Med 2023;389:1069–84,

6 - Kosiborod MN et al. N Engl J Med 2024;390:1394–407

7 - Bliddal H, Bays H, Czernichow S, Uddén Hemmingsson J, Hjelmesæth J, Hoffmann Morville T, et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. New England Journal of Medicine. 2024 Oct 31;391(17):1573–83.

8 - https://www.worldobesity.org/about/about-obesity/obesity-classification

Helpline: 021-111-455-455

Buy Now

Consult Now

Empowering Control Preserving Metabolic Health

Targets hyperglycaemia and appetite dysregulation through GLP-1 receptor activation, delivering proven HbA1c reduction and durable metabolic outcomes.

Available in pre-filled pens and vials

Once weekly convenient dosing

Helpline: 021 111 455 455

Available in pre-filled pens and vials

Once weekly convenient dosing

Helpline: 021 111 455 455

Available in pre-filled pens and vials

Once weekly convenient dosing

Helpline: 021 111 455 455

Available in pre-filled pens and vials

Once weekly convenient dosing

Helpline: 021 111 455 455

Available in pre-filled pens and vials

Once weekly convenient dosing

Helpline: 021 111 455 455

Available in pre-filled pens and vials

Once weekly convenient dosing

Helpline: 021 111 455 455

Available in pre-filled pens and vials

Once weekly convenient dosing

Helpline: 021 111 455 455

About Sem-P (Semaglutide)

Sem-P (Semaglutide) is GLP-1 receptor agonist used to

Helps control blood sugar in Type 2 Diabetes Mellitus (with diet & exercise)
Reduces risk of major cardiovascular events (heart attack, stroke, death) in high-risk patients
Supports chronic weight management in:
1. Obesity
2. Overweight with comorbidities (e.g., hypertension, diabetes, dyslipidemia)
3. Used in MASH (Metabolic Dysfunction-Associated Steatohepatitis)